HCW Biologics Inc.

Name: HCW Biologics Inc. standardized financial statements, quarterly
Creator: Listed

HCWBNasdaqCIK 1828673HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$121.7k, Q2 FY2026

Operating income−$3.2m, Q2 FY2026

Net income−$5.2m, Q2 FY2026

HCW Biologics Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.9	1.3	1.1	0.6	0.4	0.4	0.0	0.0	0.0	0.0	6.5	0.1
Cost of revenue	$m	0.7	1.1	0.5	0.4	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.2
Gross profit	$m	0.2	0.3	0.6	0.2	0.1	0.1	0.0	0.0	0.0	0.0	6.5	(0.1)
Research and development	$m	1.7	2.1	2.1	2.0	1.2	1.0	1.5	1.2	1.4	1.3	1.3	1.2
Operating income	$m	(5.1)	(10.8)	(7.5)	(15.1)	(3.7)	(3.1)	(2.0)	(3.5)	(3.3)	(4.5)	3.2	(3.2)
Interest expense	$m	0.1	(0.0)	0.0	0.2	0.2	0.3	0.3	0.2	0.1	0.2	0.1	0.1
Income tax	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported	0.0	0.3	0.0
Net income	$m	(4.9)	(10.7)	(7.5)	(15.3)	(3.9)	(3.4)	(2.2)	(1.9)	(4.6)	0.7	3.5	(5.2)
Diluted EPS	$ per share	(0.14)	not reported	(0.20)	(16.16)	(4.13)	not reported	(11.80)	(40.72)	(2.02)	not reported	1.39	(11.58)
Basic EPS	$ per share	(0.14)	not reported	(0.20)	(16.16)	(4.13)	not reported	(11.80)	(40.72)	(2.02)	not reported	1.39	(11.58)

Balance sheet

Cash and equivalents$741.3k, Q2 FY2026

Long-term debt$0, FY2025

Shareholders' equity$7.4m, Q2 FY2026

HCW Biologics Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	11.2	3.6	4.1	1.2	1.0	4.7	1.1	2.4	1.1	2.0	1.2	0.7
Current assets	$m	13.8	6.4	6.2	2.4	2.1	5.7	1.9	2.9	1.6	2.3	1.7	1.1
Total assets	$m	35.6	28.5	30.4	26.8	26.6	30.2	26.3	28.9	25.4	24.5	27.3	26.8
Current liabilities	$m	5.4	8.7	13.4	23.2	30.1	29.6	27.1	26.8	26.9	21.1	20.0	18.6
Total liabilities	$m	11.7	15.1	21.7	33.1	36.5	37.0	34.8	29.0	27.6	21.8	21.6	19.3
Long-term debt	$m	6.3	6.3	8.3	9.9	6.5	7.4	7.7	0.4	0.0	0.0	not reported	not reported
Current portion of debt	$m	0.1	0.1	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$m	not reported	0.0	not reported	not reported	6.3	6.3	6.2	6.4	6.8	6.8	6.6	6.6
Shareholders' equity	$m	23.9	13.5	8.7	(6.3)	(10.0)	(6.8)	(8.6)	(0.1)	(2.1)	2.8	5.8	7.4

Cash flow

Operating cash flow−$4.0m, Q2 FY2026

Capital expenditure$0, Q4 FY2025

HCW Biologics Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(5,589)	(3,895)	(3,604)	(4,862)	(2,926)	(2,835)	(3,514)	(3,282)	(3,240)	(3,356)	(1,575)	(3,966)
Capital expenditure	$k	630	3,716	130	(18.6)	37.1	113	0.0	0.0	0.0	0.0	not reported	not reported

Diluted shares (weighted)1.33m, Q2 FY2026

HCW Biologics Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	35.8	35.9	35.9	35.9	37.2	0.9	0.9	0.2	0.3	2.3	0.9	1.3

Shares outstanding: 1.84m at Aug 14, 2026, from the cover of the 10-Q/A filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.